Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors

NCT01572467 | Completed

• 3 other identifiers: ARAR12B2COG-ARAR12B2NCI-2012-00721
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research trial is studying genes in tumor samples from younger patients with ovarian or testicular sex cord stromal tumors.

Conditions

Childhood Germ Cell Tumor; Leydig Cell Tumor; Ovarian Cancer

Keywords

Leydig cell tumor; ovarian stromal cancer; childhood malignant testicular germ cell tumor; childhood malignant ovarian germ cell tumor

Outcome Measures

Primary Outcomes (1)

• Correlation between DICER1 mutations and miRNA pathways with outcomes using descriptive analysis

Interventions

RNA analysis GENETIC

gene expression analysis GENETIC

mutation analysis GENETIC

reverse transcriptase-polymerase chain reaction GENETIC

laboratory biomarker analysis OTHER

medical chart review OTHER

Eligibility Criteria

• Age: Up to 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients With Ovarian or Testicular Sex Cord Stromal Tumors

DISEASE CHARACTERISTICS: * Fixed and frozen tissue samples from the ATBR01 B1 tissue bank and from the International Pleuropulmonary Blastoma Registry, Children's Hospital of Boston, and Massachusetts General Hospital * Tissue samples from patients diagnosed with: * Ovarian * Sertoli-Leydig cell tumor * Juvenile granulosa cell tumor * Adult granulosa cell tumor * Gynandroblastoma * Sex cord stromal tumor with annular tubules * Sex cord stromal tumor, undifferentiated * Sertoli tumor * Leydig tumor * Testicular: * Granulosa cell tumor * Sertoli tumor * Leydig tumor * Sertoli-Leydig * Undifferentiated stromal tumor PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Leydig Cell Tumor; Ovarian Neoplasms; Testicular Neoplasms; Ovarian Germ Cell Cancer

Interventions

Gene Expression Profiling; Reverse Transcriptase Polymerase Chain Reaction

Condition Hierarchy (Ancestors)

Sertoli-Leydig Cell Tumor; Sex Cord-Gonadal Stromal Tumors; Neoplasms, Gonadal Tissue; Neoplasms by Histologic Type; Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Male Urogenital Diseases; Endocrine System Diseases; Testicular Diseases; Gonadal Disorders; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Genital Neoplasms, Female

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Polymerase Chain Reaction; Nucleic Acid Amplification Techniques

Study Officials

• Dana A. Hill, MD

  Children's National Research Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2012
• First Posted: April 6, 2012
• Study Start: April 1, 2012
• Primary Completion: July 1, 2016
• Last Updated: July 14, 2016

Record last verified: 2016-07